Browse by Vaccine Status

This page shows data for Phase 1 Vaccine Status.
Total Entries Retrieved: 93
IDVaccine NameDisease NameDisease ClassificationVirus NameNucleic Acid ContentVaccine TypeVaccine StatusManufacturerYear of ManufacturingManufacturing CountryAgeDosageAdministration RouteAdjuvantTarget StrainDescriptionApproving OrganisationCollaborating OrganisationOther CountriesTrade NamePMIDClinical Trial IDReference LinkAdditional Links
10146 KCONVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 1 Beijing Minhai Biotechnology Co. Ltd. 2021 China 18 years and above NA Intramuscular NA NA NA NA NA NA NA NA NCT04758273 https://clinicaltrials.gov/show/NCT04758273 https://covid-19pharmacovigilance.paho.org/sinopharmbibp
10147 CoV2-OGEN1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 US Specialty Formulations, VaxForm LLC. 2021 New Zealand 18 - 56 years 2 doses 14 days apart Intramuscular NA NA NA NA NA NA NA NA NCT04893512 https://clinicaltrials.gov/show/NCT04893512 NA
10148 MVA-SARS-2-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Universitätsklinikum Hamburg-Eppendorf 2021 Germany 18 - 55 years 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA Ludwig-Maximilians, University of Munich NA NA NA NCT04569383 https://clinicaltrials.gov/show/NCT04569383 NA
10149 OSE13E COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 OSE Immunotherapeutics 2021 Belgium 18 - 45 years 2 doses 21 days apart Subcutaneous NA 11 different proteins of SARS-CoV-2 virus NA NA NA NA CoVepiT NA NCT04885361 https://clinicaltrials.gov/show/NCT04885361 NA
10150 Covigenix VAX-001 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Entos Pharmaceuticals Inc. 2020 Canada 18 - 85 years 2 doses 14 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus Fusogenix PLV NA Canadian Institutes of Health Research NA NA NA NCT04591184 https://clinicaltrials.gov/ct2/show/NCT04591184 https://clinicaltrials.gov/ct2/history/NCT04591184
10151 Covovax (Nuvaxovid) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 Novavax Inc. NA NA NA NA Intramuscular Matrix-M1 Spike protein of SARS-CoV-2 virus NA NA NA NA TAK-019, SARS-CoV-2 rS 32585611 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301105/ https://clinicaltrials.gov/ct2/show/NCT04368988
10152 bacTRL-Spike vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Symvivo Corporation NA NA 18 - 59 years NA Oral NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA 32585611 NCT04334980 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301105/ NA
10153 AdCOVID COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 Altimmune Inc. NA USA 18 - 55 years NA Intranasal NA NA NA NA NA NA NA 33937326 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10154 MVA-SARS-2-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 University Medical Center Hamburg-Eppendorf NA Germany 18 - 55 years NA Intramuscular NA NA NA NA NA NA NA 33937326 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10155 MVA-SARS-2-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 Ludwig-Maximilians, University of Munich NA NA NA 2 doses 28 days apart Intramuscular NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10156 VXA-CoV2-1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Vaxart 2021 USA 18 - 55 years 2 doses 28 days apart Oral NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA 33937326 NCT04563702 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10157 VXA-CoV2-1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Vaxart 2021 USA 18 - 54 years 2 doses 28 days apart Oral NA NA Ad5 adjuvanted Oral Vaccine platform NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10158 GRAd-COV2 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 ReiThera Srl 2021 Italy 18 - 85 years NA Intramuscular NA NA NA NA NA NA NA 33937326 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10159 KCONVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 1 Shenzhen Kangtai Biological Products Co. Ltd NA NA NA 1- 3 doses depending on volume and age Intramuscular NA NA NA NA NA NA Inactivated SARS-CoV-2 vaccine (Vero cell) 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10160 CVXGA1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 CyanVac LLC 2021 USA 18 - 75 years Single dose Intranasal NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA PIV5-SARS CoV-2 vaccine NA NCT04954287 https://clinicaltrials.gov/ct2/show/NCT04954287 NA
10161 COVID-19 rNDV vector vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Laboratorio Avi-Mex 2021 Mexico 18 - 55 years 2 doses 21 days apart Intramuscular NA NA NA NA NA NA NA NA NCT04871737 https://clinicaltrials.gov/ct2/show/study/NCT04871737 NA
10162 COVI-VAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Live-attenuated Phase 1 Codagenix Inc. 2021 UK 18 - 30 years 2 doses 28 days apart Intranasal NA SARS CoV 2 whole virus NA NA Serum Institute of India NA CDX-005 33816047 NCT04619628 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10163 BriLife COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 1 Israel Institute for Biological Research NA NA NA Single dose Intramuscular NA NA NA NA NA NA rVSV-SARS-CoV-2-S Vaccine 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10164 bacTRL-Spike vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Symvivo Corporation NA NA NA Single dose Oral NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10165 Koçak-19 Inaktif Covid-19 Vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 1 Kocak Farma 2021 Turkey 18 - 55 years 2 doses 21 days apart Intramuscular NA SARS CoV 2 whole virus NA NA NA NA NA NA NCT04838080 https://clinicaltrials.gov/ct2/show/NCT04838080 NA
10166 ChulaCov19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Chulalongkorn University NA NA NA 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10167 CORVax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Providence Health & Services NA NA NA 2 doses 14 days apart Intradermal NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10168 Covigenix VAX-001 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Entos Pharmaceuticals Inc. 2021 Canada NA 2 doses 14 days apart Intramuscular NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10169 AdimrSC-2f COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 Adimmune Corporation 2021 Taiwan 20 - 60 years NA Intramuscular Aluminum Recombinant receptor binding domain of SARS-CoV-2 spike protein NA NA NA NA NA 33816047 NCT04522089 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://clinicaltrials.gov/ct2/show/NCT05104489
10170 Shingrix COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 University of Oklahoma  NA NA NA 2 doses 60 days apart Intramuscular NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10171 SARS-CoV-2 VLP vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 1 The Scientific and Technological Research Council of Turkey 2021 Turkey 18 - 45 years 2 doses 21 days apart Subcutaneous Alumium hydroxide, CpG ODN Inactivated SARS-CoV-2 virus NA NA NA NA NA NA NCT04866069 https://clinicaltrials.gov/ct2/show/study/NCT04866069 NA
10172 COVID-19 aAPC vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 1 Shenzhen Geno-Immune Medical Institute 2021 China 6 months - 80 years 3 doses on day 0, 14 and 28 Subcutaneous NA NA The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with immune-modulatory genes and the viral minigenes to the artificial antigen-presenting cells NA NA NA NA 33816047 NCT04299724 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10173 SARS-CoV-2 mRNA vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Shulan (Hangzhou) Hospital NA NA NA 2 doses 14 days apart Intramuscular NA NA NA NA Guangxi CDC NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10174 LNP-nCoVsaRNA COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Imperial College London 2021 UK 18 - 75 years 2 doses Intramuscular NA Self-amplifying RNA SARS-CoV-2 lipid nanoparticle NA NA NA NA COVAC1 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10175 MV-014-212 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Live-attenuated Phase 1 Meissa Vaccines Inc. 2021 USA 18 - 69 years 2 doses 35 days apart Intranasal NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04798001 https://clinicaltrials.gov/ct2/show/NCT04798001?term=covid-19+vaccine&draw=2 NA
10176 Noora vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 Bagheiat-allah University of Medical Sciences 2021 Iran 18 - 50 years 3 doses on day 0, 21 and 35 Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA AmitisGen NA NA https://en.irct.ir/trial/56987 NA
10177 COVAX-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 Vaxine, Medytox NA NA NA Single dose Intramuscular NA NA NA NA NA NA COVID-19 vaccine 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10178 SpFN COVID-19 Vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 US Army Medical Research and Development Command 2021 USA 18 - 55 years 3 doses on day 1, 29 and 181 Intramuscular Army Liposomal Formulation QS21 Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA NA NCT04784767 https://clinicaltrials.gov/show/NCT04784767 NA
10179 ChAdV68-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Gritstone Oncology 2021 USA 18 years and above 2 doses 28 days apart Intramuscular Aluminum (alum) SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA NA NCT04760743 https://clinicaltrials.gov/ct2/show/NCT04760743 NA
10180 iNCOVACC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 Bharat Biotech International Limited 2021 India 18 - 60 years 2 doses 28 days apart Intranasal NA Spike protein of SARS-CoV-2 virus NA NA NA NA BBV154 NA NA http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=51327 NA
10181 PTX-COVID19-B COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Providence Therapeutics Holdings Inc. 2021 Canada 18 - 64 years 2 doses 28 days apart Intramuscular NA NA NA NA NA NA NA NA NCT04765436 https://clinicaltrials.gov/show/NCT04765436 NA
10182 ReCOV COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 Jiangsu Rec-Biotechnology Co. Ltd. 2021 New Zealand 18 - 60 years 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04818801 https://clinicaltrials.gov/ct2/show/NCT04818801 NA
10183 NBP2001 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 SK Bioscience Co. Ltd. 2021 South Korea 19 - 55 years 2 doses 28 days apart Intramuscular MF59 SARS CoV-2 Receptor Binding domain NA NA NA NA NA NA NCT04760743 https://clinicaltrials.gov/show/NCT04760743 NA
10184 SC-Ad6-1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Tetherex Pharmaceuticals Corporation 2021 Australia 18 - 55 years Single or multiple-dose Intramuscular, Intranasal NA NA NA NA NA NA NA NA NCT04839042 https://clinicaltrials.gov/ct2/show/NCT04839042 NA
10185 Turkovac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 1 Health Institutes of Turkey 2020 Turkey 18 - 55 years 2 doses 21 days apart Intramuscular NA NA NA NA NA NA ERUCOV-VAC NA NCT04691947 https://clinicaltrials.gov/show/NCT04691947 NA
10186 bacTRL-Spike vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Symvivo Corporation 2020 Australia 18 years and above NA Oral NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04334980 https://clinicaltrials.gov/show/NCT04334980 NA
10187 Spikevax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Moderna Inc. 2021 USA 18 years and above 2 doses 28 days apart Intramuscular NA NA mRNA based vaccine US FDA NA NA mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran NA NCT04785144 https://clinicaltrials.gov/ct2/show/NCT04785144 NA
10188 Covax-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 GeneCure Biotechnologies 2020 USA 18 - 60 years 2 doses 2 weeks apart Intramuscular NA NA NA US FDA NA NA NA NA NCT04428073 https://clinicaltrials.gov/show/NCT04428073 https://delta.larvol.com/Products/bac627c1e3c7453f9c3e06990d38d930/COVAX19GC004/0/11eb4d064c904d80ad7af09be3dfc6e8/COVAX19-Monovalent-Recombinant-COVID19-Vaccine/
10189 TMV-083 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 1 Institut Pasteur 2020 Belgium 18 - 55 years 2 doses 28 days apart Intramuscular NA Surface glycoprotein of the SARS-CoV-2 NA NA NA NA MV-SARS-CoV-2 NA NCT04497298 https://clinicaltrials.gov/show/NCT04497298 NA
10190 IN01 vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA NA Phase 1 Instituto Oncolâ—Žgico Dr Rosell 2020 Spain 18 years and above NA NA NA NA NA NA NA NA NA NA NCT04537130 https://clinicaltrials.gov/show/NCT04537130 NA
10191 V590-001 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 1 Merck & Co. Inc. 2020 USA 18 years and above NA Intramuscular NA NA NA US FDA NA NA NA NA NCT04569786 https://clinicaltrials.gov/show/NCT04569786 NA
10192 CoV2 SAM COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 GlaxoSmithKline 2021 USA 18 - 50 years 2 doses 1 month apart Intramuscular NA Spike protein of SARS-CoV-2 virus mRNA based vaccine NA NA NA NA NA NCT04758962 https://clinicaltrials.gov/ct2/show/study/NCT04758962 NA
10193 CORVax12 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Providence Health & Services, OncoSec Medical Inc. 2021 USA 18 years and above NA Intradermal NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA NA NCT04627675 https://clinicaltrials.gov/ct2/show/NCT04627675 NA
10194 ChulaCov19 mRNA vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Chulalongkorn University 2021 Thailand 18 - 75 years 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04566276 https://clinicaltrials.gov/show/NCT04566276 NA
10195 ChAdOx1 MERS (MERS002) MERS Respiratory MERS-CoV positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 King Abdullah International Medical Research Center 2020 Saudi Arabia 18 - 50 years NA Intramuscular NA Eplication-deficient simian adenoviral vector expressing the spike protein of MERS Coronavirus NA NA University of Oxford NA NA NA NCT04170829 https://clinicaltrials.gov/ct2/show/NCT04170829?cond=MERS-CoV&phase=0123&draw=2&rank=3 NA
10196 MVA-MERS-S MERS Respiratory MERS-CoV positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Philipps University Marburg Medical Center 2020 Germany 18 - 55 years 2 doses 28 days apart Intramuscular NA MERS CoV spike glycoprotein NA NA NA NA NA 32325037 NCT03615911 https://pubmed.ncbi.nlm.nih.gov/32325037/ NA
10197 MVA-MERS-S_DF1 MERS Respiratory MERS-CoV positive-sense, single-stranded RNA Recombinant viral vector Phase 1 CTC North GmbH & Co. KG 2021 Germany 18 - 55 years NA Intramuscular NA MERS CoV spike glycoprotein NA NA NA NA NA 33341119 NCT04119440 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749790/ NA
10198 Inactivated SARS-CoV vaccine (ISCV) SARS Respiratory SARS-CoV positive-sense, single-stranded RNA Inactivated Phase 1 Sinovac Biotech Ltd. NA China NA NA NA CpG 1018, alum SARS CoV NA NA NA NA NA 33341119 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749790/ NA
10199 VRC-SRSDNA015-00-VP SARS Respiratory SARS-CoV positive-sense, single-stranded RNA DNA based vaccine Phase 1 National Institute of Allergy and Infectious Diseases 2017 USA 18 - 50 years NA Intramuscular NA SARS CoV spike glycoprotein NA NA NA NA NA 33341119 NCT00099463 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749790/ NA
10200 Ad5-EBOV Ebola Hemorrhagic Zaire ebolavirus negative-sense, single-stranded RNA Non-replicating viral vector Phase 1 National Institute of Health 2010 USA 18 - 50 years NA Intramuscular NA Ebola virus envelope glycoprotein NA NA National Institute of Allergy and Infectious Diseases NA NA 27764560 NCT00374309 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/ https://www.precisionvaccinations.com/vaccines/ad5-ebov-ebola-vaccine#:~:text=CanSinBio%20Ad5%2DEBOV%20is%20an,type%2D5%20vector%20immune%20response.
10201 DNA Ebola Hemorrhagic Zaire ebolavirus negative-sense, single-stranded RNA DNA based vaccine Phase 1 National Institute of Health 2003 USA 18 - 44 years NA NA NA NA NA NA National Institute of Allergy and Infectious Diseases NA NA 27764560 NCT00072605 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/ NA
10202 rVSV-EBOV Ebola Hemorrhagic Zaire ebolavirus negative-sense, single-stranded RNA Recombinant viral vector Phase 1 Merck & Co. Inc. 2014 USA 18 - 65 years NA Intramuscular NA Zaire Ebola virus glycoprotein Vesicular Stomatitis Virus based NA National Institute of Allergy and Infectious Diseases NA NA 27764560 NCT02280408 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/ NA
10203 Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO)/ChAd3-EBO-Z Ebola Hemorrhagic Zaire ebolavirus negative-sense, single-stranded RNA Recombinant viral vector Phase 1 National Institute of Allergy and Infectious Diseases 2014 USA 18 - 65 years NA Intramuscular NA Wild type glycoproteins from Zaire and Sudan strains of Ebolavirus Chimpanzee Adenovirus Vector expressing Zaire and sudan strain glycoprotein NA NA NA NA 27764560 NCT02231866 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/ NA
10204 HPIV3-EBO-Z ( HPIV3-EbovZ GP Vaccine) Ebola Hemorrhagic Zaire ebolavirus negative-sense, single-stranded RNA Virus like particle Phase 1 Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health 2015 USA 18 - 50 years NA Intranasal NA Zaire Ebola virus glycoprotein Live-attenuated human Parainfluenza virus type 3 vectored vaccine expressing Ebolavirus Zaire glycoprotein NA National Institute of Allergy and Infectious Diseases NA NA 27764560 NCT02564575 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/ NA
10205 KIRIM-KONGO-VAX Crimean-Congo haemorrhagic fever Hemorrhagic Nairovirus negative-sense, single-stranded RNA NA Phase 1 The Scientific and Technological Research Council of Turkey 2017 Turkey 18 - 55 years NA Subcutaneous, Intramuscular NA NA NA NA NA NA NA NA NCT03020771 https://clinicaltrials.gov/ct2/show/NCT03020771?cond=Crimean-Congo+hemorrhagic+fever&draw=2&rank=1 https://ichgcp.net/clinical-trials-registry/NCT03020771
10206 GEO-EM05 Marburg hemorrhagic fever Hemorrhagic Marburg virus negative-sense, single-stranded RNA Virus like particle Phase 1 GeoVax Labs Inc. NA USA NA NA Intramuscular NA NA NA NA NA NA NA NA NA https://www.biospace.com/article/geovax-announces-100-percent-protection-data-from-marburg-virus-vaccine-study/ NA
10207 AVI-6003 Marburg hemorrhagic fever Hemorrhagic Marburg virus negative-sense, single-stranded RNA NA Phase 1 Sarepta Therapeutics Inc. 2012 USA 18 - 55 years NA Intravenous NA NA NA NA NA NA NA NA NCT01353040 https://clinicaltrials.gov/ct2/show/NCT01353040?cond=Marburg+hemorrhagic+fever&draw=2&rank=1 NA
10208 cAd3 Marburg (VRC-MARADC087-00-VP) Marburg hemorrhagic fever Hemorrhagic Marburg virus negative-sense, single-stranded RNA Recombinant viral vector Phase 1 National Institute of Allergy and Infectious Diseases 2021 USA 18 - 50 years Single dose Intramuscular NA Marburg wild type glycoprotein NA US FDA US Military HIV Research Program NA NA NA NCT03475056 https://clinicaltrials.gov/ct2/show/NCT03475056?cond=Marburg+hemorrhagic+fever&draw=2&rank=3 NA
10209 XRX-001 Inactivated yellow fever vaccine Yellow fever Hemorrhagic Yellow fever virus positive-sense, single-stranded RNA Inactivated Phase 1 GE Healthcare 2016 USA 18 - 49 years NA NA Aluminum (alum) Yellow fever virus NA NA NA NA NA NA NCT00995865 https://clinicaltrials.gov/ct2/show/NCT00995865?recrs=abde&cond=yellow+fever&phase=0123&draw=2&rank=4 NA
10210 DENV-1 PIV Dengue fever Hemorrhagic Dengue virus positive-sense, single-stranded RNA Inactivated Phase 1 US Army Medical Research and Development Command 2015 USA 18 - 50 years 2 doses 28 days apart Intramuscular NA Dengue virus serotypes -1 NA NA NA NA NA NA NCT01502735 https://clinicaltrials.gov/ct2/show/NCT01502735?recrs=abde&cond=dengue+fever&phase=0123&draw=2&rank=5 NA
10211 rDEN3delta30/31-7164 Dengue fever Hemorrhagic Dengue virus positive-sense, single-stranded RNA Live-attenuated Phase 1 National Institute of Allergy and Infectious Diseases 2013 USA 18 - 50 years NA Subcutaneous NA Dengue virus serotypes -3 NA NA Johns Hopkins Bloomberg School of Public Health NA NA NA NCT00831012 https://clinicaltrials.gov/ct2/show/NCT00831012?recrs=abde&cond=dengue+fever&phase=0123&draw=2&rank=12 NA
10212 MV-LASV (V182-001) Lassa fever Hemorrhagic Lassa virus negative-sense, single-stranded RNA Live-attenuated Phase 1 Themis Bioscience 2021 Belgium 18 - 55 years 2 doses 28 days apart Intramuscular NA Measles Schwarz virus strain for prophylaxis of Lassa infection NA NA NA NA NA NA NCT04055454 https://clinicaltrials.gov/ct2/show/NCT04055454?cond=Lassa+fever&draw=2&rank=10 NA
10213 GSK HSV Vaccine Genital Herpes Cutaneous Herpes simplex virus double stranded DNA RNA based vaccine Phase 1 GlaxoSmithKline 2021 UK 18 - 40 years 2 doses at interval of 2 months Intramuscular NA Herpes simplex virus 2 glycoprotein D (gD-2) mRNA based vaccine US FDA NA NA NA NA NA https://www.precisionvaccinations.com/vaccines/herpes-vaccine-candidates https://www.precisionvaccinations.com/vaccines/hsv-2-vaccine-gsk4108771a#:~:text=The%20herpes%20simplex%20virus%20type,genetic%20code%20of%20a%20virus.
10214 RH-CHIKV EV-CHIKV RHEV-CHIKV Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Live-attenuated Phase 1 NA NA NA NA Single dose Footpad injection NA R532H-nsP, E515V-nsP2 NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10215 Delta 5nsP3 DREP-E MVA-CE Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Live-attenuated Phase 1 NA NA NA NA Single dose Subcutaneous NA CHIKV nsP3 envelope and capsid protein NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10216 Ad-CHIKV-SG Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Virus like particle Phase 1 NA NA NA NA Single dose Intranasal NA CHIKV structural proteins NA NA NA NA Ad-CHIKV-E3/E2/6K, Ad-CHIKV-E3/E2/E1 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10217 ChAdOx1-sCHIKV Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Virus like particle Phase 1 NA NA NA NA Single dose Intramuscular NA CHIKV structural proteins NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10218 VSV G-CHIKV Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Virus like particle Phase 1 NA NA NA NA Single dose Intramuscular NA CHIKV envelope proteins (E1, E2, and E3) NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10219 dMAb Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 NA NA NA NA NA Intramuscular NA CHIKV envelope proteins (E1, E2, and E3) NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10220 pCHIKV-7 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 NA NA NA NA NA NA NA cDNA of 181/25 NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10221 CHKV-24 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 NA NA NA NA Single dose Intravenous NA NA NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10222 VRC-CHKVLP059-00-VP Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Virus like particle Phase 1 National Institute of Health 2016 USA 18 - 50 years 10 ug at weeks 0, 4, and 20 Intramuscular NA Human HEK293 cells NA NA National Institute of Allergy and Infectious Diseases NA NA NA NCT01489358 https://clinicaltrials.gov/ct2/show/NCT01489358 NA
10223 USAMRIID Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Live-attenuated Phase 1 NA NA NA NA 1- 2 doses depending on volume and age NA NA NA Formalin inactivated produced in green monkey kidney cells or chick embryonic cells NA NA NA NA NA NA https://academic.oup.com/jid/article/214/suppl_5/S488/2632628 NA
10224 VLP- NIH Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Virus like particle Phase 1 NA NA NA NA 3 doses NA NA NA Produced from DNA transfected into human embryonic kidney VRC293 NA NA NA NA NA NA https://academic.oup.com/jid/article/214/suppl_5/S488/2632628 NA
10225 Measles-CHIKV Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Live-attenuated Phase 1 NA NA NA NA Single dose NA NA CHIKV proteins Recombinant measles virus (Schwartz strain) expressing CHIKV VLPs NA NA NA NA NA NA https://academic.oup.com/jid/article/214/suppl_5/S488/2632628 NA
10226 TSI-GSD-218 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Live-attenuated Phase 1 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 NA
10227 CHIKV Delta 5nsP3 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Live-attenuated Phase 1 NA NA NA NA NA NA NA Clinical strain attenuated by targeted mutations in nsP3, 6 K NA NA NA NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 NA
10228 CHIK001 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 University of Oxford 2019 NA 18 - 50 years NA NA NA Chimpanzee adenovirus expressing CHIKV structural proteins NA NA NA NA NA NA NCT03590392 https://link.springer.com/chapter/10.1007/82_2019_175 https://clinicaltrials.gov/ct2/show/NCT03590392?cond=Chickungunya+Fever&draw=2&rank=29
10229 mRNA-1944 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Moderna Inc. 2021 USA 18 - 50 years NA NA NA CHIKV-directed monoclonal antibody NA US FDA Defense Advanced Research Projects Agency NA NA NA NCT03829384 https://link.springer.com/chapter/10.1007/82_2019_175 https://clinicaltrials.gov/ct2/show/NCT03829384
10230 mRNA-1388 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Moderna Inc. 2017 USA 18 - 49 years 3 doses on week 0, week 4, post 1 year Intramuscular NA CHIKV structural proteins mRNA based vaccine NA Defense Advanced Research Projects Agency NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 https://www.modernatx.com/pipeline/mrna-1388
10231 VLA1533 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Valneva 2019 Austria 18 - 39 years 3 doses on day 0, 28 and 56 Intramuscular NA NA NA NA NA NA NA NA NCT03010228 https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919 https://clinicaltrials.gov/ct2/show/NCT03010228
10232 VAL-181388 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Moderna Inc. 2017 USA 18 - 49 years 3 doses on week 0, week 4, post 1 year NA NA NA NA US FDA Defense Advanced Research Projects Agency NA NA NA NCT03325075 https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919 https://clinicaltrials.gov/ct2/show/NCT03325075
10233 IRES-CHIKV Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Live-attenuated Phase 1 University of Texas Medical Branch, Takeda Pharmaceutical Company Limited 2011 USA NA NA Subcutaneous NA La Reunion strain NA NA NA NA NA NA NA https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145802/
10234 EILV/CHIKV Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Virus like particle Phase 1 University of Texas Medical Branch 2017 USA NA NA NA NA CHIKV structural proteins NA NA NA NA NA NA NA https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296253/
10235 VXA G1.1 NN Norovirus Infection Gastrointestinal Norovirus positive-sense, single-stranded RNA Virus like particle Phase 1 Vaxart NA USA NA NA Intranasal NA HuNoV GII.4 NA NA NA NA NA NA NA https://www.mdpi.com/2076-393X/9/7/732/htm NA
10236 Monovalent GI.1 VLPs Norovirus Infection Gastrointestinal Norovirus positive-sense, single-stranded RNA Virus like particle Phase 1 Baylor College of Medicine, University of Maryland School of Medicine NA USA NA NA Intranasal MPL HuNoV GI.1 NA NA NA NA NA NA NA https://www.mdpi.com/2076-393X/9/7/732/htm NA
10237 Transgenic plant-based norovirus vaccine Norovirus Infection Gastrointestinal Norovirus positive-sense, single-stranded RNA Virus like particle Phase 1 Arizona State University NA USA NA NA Intranasal Gardiquimod, None when delivered with GelVac Norwalk virus (GI.1) VLP Tobacco mosaic virus derived transient expression system using leaves of Nicotiana benthamiana NA NA NA NA NA NA https://www.cdc.gov/norovirus/downloads/global-burden-report.pdf NA
10238 BG505 mRNA Acquired Immunodeficiency Syndrome (AIDS) Other Human Immunodeficiency Virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 National Institute of Allergy and Infectious Diseases 2022 USA 18 - 55 years NA Intramuscular NA BG505 MD39 mRNA NA NA National Institutes of Health NA NA NA NCT05217641 https://clinicaltrials.gov/ct2/show/NCT05217641 https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trial-three-mrna-hiv-vaccines